Eric Aguiar, M.D. joins Connecticut office as Partner and Jason Brown, Ph.D. joins San Francisco office as Associate

STAMFORD, CT & SAN FRANCISCO, CA– OCTOBER 17, 2007 - Thomas, McNerney & Partners, LLC, a health care venture capital firm that invests in life science and medical technology companies, today announced that Eric Aguiar, M.D., has joined as a partner in the firm’s Connecticut office. Since 2001, Dr. Aguiar has been a managing director in the Boston and Princeton offices of HealthCare Ventures.

“Eric’s deep experience in venture capital and biopharmaceutical operations complements our multi-faceted team and helps to further expand our reach along the East Coast,” said James Thomas, partner. “His investment expertise and operational experience will be an asset to the firm as he builds upon our core strengths in identifying, financing and building biopharmaceutical opportunities.”

Dr. Aguiar has more than 12 years of venture capital experience, most recently as managing director of HealthCare Ventures. Prior to joining HealthCare Ventures, he was chief executive officer of Genovo Inc., a biopharmaceutical company specializing in gene delivery and gene regulation. Prior to Genovo, Dr. Aguiar served as an executive director at TheraTech, Inc., which was later acquired by Watson Pharmaceuticals. For five years he was also managing director of Philadelphia Ventures where he served on the board of several biotechnology companies. Dr. Aguiar is also a member of the board of overseers of the Tufts School of Medicine.

“Thomas, McNerney & Partners’ broad mandate to invest in companies at all stages of development in a variety of health care sectors and its history of success in leading its portfolio investments is what attracted me to the firm,” said Dr. Aguiar. “I look forward to joining the partnership and expanding the firm’s capabilities in the biopharmaceuticals sector.”

In addition to Dr. Aguiar, Jason Brown, Ph.D. joined the firm as an associate in the San Francisco office. Dr. Brown was most recently a member of the investment team at Forward Ventures, where he played an active role in Forward-led rounds of investment totaling more than $50 million. Prior to joining Forward, he conducted research in antimicrobial drug discovery and bacterial genomics as a postdoctoral fellow in Infectious Diseases at Johnson & Johnson Pharmaceutical Research and Development.

About Thomas, McNerney & Partners
Thomas, McNerney & Partners is a health care venture capital firm with approximately $600 million under management focused on investing in life science and medical technology companies at all stages of development. In addition to helping entrepreneurs launch companies with seed and early stage funding, the firm provides growth capital to emerging companies to advance clinical development or for product commercialization. Thomas, McNerney & Partners also is involved in spinning out products and divisions from major medical device and pharmaceutical companies, consolidating companies through roll-up strategies and participating in structured financings for public companies as well as recapitalizations. The firm is targeting investments in the pharmaceutical, medical device, biotechnology and diagnostic sectors and in other areas utilizing medical technology innovation. The firm has offices in Stamford , Minneapolis and San Francisco . For further information, please visit